Assessing the psychedelic “after-glow” in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities
This open-label study (n=16) investigated neurometabolic and connectivity modifications after a single ayahuasca use and their association with mindfulness measures. The results support the involvement of glutamate neurotransmission in the effects of ayahuasca. Furthermore, changes in the posterior cingulate cortex (default network) and connection of the posterior cingulate cortex and the medial temporal lobe (emotion & memory) may contribute to the effects of ayahuasca.
Authors
- Jordi Riba
- Jamie Hallak
- Amanda Feilding
Published
Abstract
Background
Ayahuasca is a plant tea containing the psychedelic 5-HT2A agonist N,N-dimethyltryptamine and harmala monoamine-oxidase inhibitors. Acute administration leads to neurophysiological modifications in brain regions of the default mode network, purportedly through a glutamatergic mechanism. Post-acutely, ayahuasca potentiates mindfulness capacities in volunteers and induces rapid and sustained antidepressant effects in treatment-resistant patients. However, the mechanisms underlying these fast and maintained effects are poorly understood. Here, we investigated in an open-label uncontrolled study in 16 healthy volunteers ayahuasca-induced post-acute neurometabolic and connectivity modifications and their association with mindfulness measures.
Methods
Using 1H-magnetic resonance spectroscopy and functional connectivity, we compared baseline and post-acute neurometabolites and seed-to-voxel connectivity in the posterior and anterior cingulate cortex after a single ayahuasca dose.
Results
Magnetic resonance spectroscopy showed post-acute reductions in glutamate+glutamine, creatine, and N-acetylaspartate+N-acetylaspartylglutamate in the posterior cingulate cortex. Connectivity was increased between the posterior cingulate cortex and the anterior cingulate cortex, and between the anterior cingulate cortex and limbic structures in the right medial temporal lobe. Glutamate+glutamine reductions correlated with increases in the “nonjudging” subscale of the Five Facets Mindfulness Questionnaire. Increased anterior cingulate cortex-medial temporal lobe connectivity correlated with increased scores on the self-compassion questionnaire. Post-acute neural changes predicted sustained elevations in nonjudging 2 months later.
Conclusions
These results support the involvement of glutamate neurotransmission in the effects of psychedelics in humans. They further suggest that neurometabolic changes in the posterior cingulate cortex, a key region within the default mode network, and increased connectivity between the anterior cingulate cortex and medial temporal lobe structures involved in emotion and memory potentially underlie the post-acute psychological effects of ayahuasca.
Research Summary of 'Assessing the psychedelic “after-glow” in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities'
Introduction
Psychedelics have regained research interest for their potential therapeutic effects in psychiatry. Ayahuasca is an Amazonian brew combining DMT, a 5-HT2A agonist, with β-carbolines that inhibit monoamine oxidase and enable oral activity of DMT. Acute ayahuasca administration produces intense introspective states and measurable neurophysiological changes in nodes of the default mode network (DMN), particularly the posterior cingulate cortex (PCC), while radiotracer studies point to increased activity in limbic and cingulate regions involved in emotion and memory. Previous clinical reports have also documented rapid and sustained antidepressant effects and post-acute increases in mindfulness-related capacities after single doses, but the neural mechanisms that might underlie these sustained or "after-glow" effects remain unclear. Sampedro and colleagues set out to characterise post-acute (within 24 hours) neurometabolic and resting-state functional connectivity changes after a single ayahuasca session in healthy volunteers, and to test whether those neural changes relate to enhancements in mindfulness capacities measured immediately and at a 2-month follow-up. They focused on the PCC and anterior cingulate cortex (ACC) as a priori regions of interest and hypothesised: (1) post-acute decreases in Glx (combined glutamate plus glutamine) and energy metabolites in PCC and ACC reflecting prior excitatory effects; (2) reduced PCC–ACC anticorrelation (increased coupling) paralleling neurometabolic changes; and (3) correlations between neural changes and increases in mindfulness measures both post-acutely and at follow-up. The study is an open-label, within-subject pre/post assessment in experienced ayahuasca users.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Authors
- APA Citation
Sampedro, F., de la Fuente Revenga, M., Valle, M., Roberto, N., Domínguez-Clavé, E., Elices, M., Luna, L. E., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., Friedlander, P., Barker, S. A., Álvarez, E., Soler, J., Pascual, J. C., Feilding, A., & Riba, J. (2017). Assessing the psychedelic “after-glow” in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities. International Journal of Neuropsychopharmacology, 20(9), 698-711. https://doi.org/10.1093/ijnp/pyx036
References (32)
Papers cited by this study that are also in Blossom
Rodríguez-Fornells, A., Ribeiro, S., Sanches, R. F. et al. · European Neuropsychopharmacology (2015)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Carhart-Harris, R. L., Leech, R., Erritzoe, D. et al. · Schizophrenia Bulletin (2012)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M. et al. · Psychological Medicine (2016)
De Araujo, D. B., Ribeiro, S., Cecchi, G. A. et al. · Human Brain Mapping (2011)
Dolder, P. C., Schmid, Y., Müller, F. et al. · Neuropsychopharmacology (2016)
Domínguez-Clavé, E., Soler, J., Elices, M. et al. · Brain Research Bulletin (2016)
Frecska, E., Móré, C. E., Vargha, A. et al. · Journal of Psychoactive Drugs (2012)
Show all 32 referencesShow fewer
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Lebedev, A. V., Kaelen, M., L€ Ovd En, M. et al. · Human Brain Mapping (2016)
McKenna, D., Towers, G. H., Abbott, F. · Journal of Ethnopharmacology (1984)
Osório, F. L., Sanches, R. F., Macedo, L. et al. · brazilian Journal of Psychiatry (2015)
Palhano-Fontes, F., Andrade, K. C., Tófoli, L.F. et al. · PLOS ONE (2015)
Preller, K. H., Pokorny, D., Hock, A. et al. · PNAS (2016)
Riba, J., Urbano, G., Morte, A. et al. · Psychopharmacology (2001)
Riba, J., Valle, M., Urbano, G. et al. · Journal of Pharmacology and Experimental Therapeutics (2003)
Riba, J., Anderer, P., Jané, F. et al. · Neuropsychobiology (2004)
Roseman, L., Leech, R., Feilding, A. et al. · Frontiers in Human Neuroscience (2014)
Sanches, R. F., Osório, F. L., Dos Santos, R. G. et al. · Journal of Clinical Psychopharmacology (2016)
Schenberg, E. E., Alexandre, J. F. M., Filev, R. et al. · PLOS ONE (2015)
Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)
Sessa, B. · British Journal of Psychiatry (2018)
Soler, J., Elices, M., Franquesa, A. et al. · Psychopharmacology (2015)
Tagliazucchi, E., Roseman, L., Kaelen, M. et al. · Current Biology (2016)
Valle, M., Maqueda, A. E., Rabella, M. et al. · European Neuropsychopharmacology (2016)
Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)
Winkelman, M. J. · Current Drug Abuse Reviews (2014)
Cited By (69)
Papers in Blossom that reference this study
Lima, G., Soares, C., Teixeira, M. et al. · Scientific Reports (2025)
Egger, K., Meling, D., Polat, F. et al. · Imaging Neuroscience (2025)
Soto-Angona, Ó., Andión, O., Sabucedo, P. et al. · Scientific Reports (2025)
Aicher, H. D., Wicki, I. A., Meling, D. et al. · Journal of Psychopharmacology (2025)
Calder, A. E., Hase, A., Hasler, G. · Molecular Psychiatry (2024)
Meling, D., Egger, K., Aicher, H. D. et al. · Journal of Psychopharmacology (2024)
Bagdasarian, F. A., Hansen, H. D., Chen, J. et al. · ACS Chemical Neuroscience (2024)
Sloshower, J. A., Zeifman, R. J., Guss, J. et al. · Scientific Reports (2024)
Agin-Liebes, G. I., Nielson, E. M., Zingman, M. et al. · Psychology of Addictive Behaviors (2024)
Mason, N. L., Szabo, A., Kuypers, K. P. C. et al. · Brain Behavior and Immunity - Health (2023)
Show all 69 papersShow fewer
Mallaroni, P., Mason, N. L., Kloft, L. et al. · Frontiers in Neuroscience (2023)
Ramaekers, J. G., Mallaroni, P., Kloft, L. et al. · Journal of Cognitive Neuroscience (2023)
Winkelman, M. J., Szabo, A., Frecska, E. · European Neuropsychopharmacology (2023)
Azmoodeh, K., Thomas, E., Kamboj, S. K. · Experimental and Clinical Psychopharmacology (2023)
Sjöstedt-Hughes, P. · Frontiers in Psychology (2023)
Brasher, T., Rosen, D., Spinella, M. · International Journal of Wellbeing (2023)
Timmermann, C., Vollenweider, F. X. · Trends in Cognitive Sciences (2023)
Perkins, D., Ruffell, S. G. D., day, K. et al. · Frontiers in Neuroscience (2023)
Bouso, J. C., Andión, O., Sarris, J. et al. · PLOS Global Public Health (2022)
Gattuso, J. J., Perkins, D., Ruffell, S. G. D. et al. · International Journal of Neuropsychopharmacology (2022)
Ornelas, I. M., Cini, F. A., Wießner, I. et al. · Experimental Neurology (2022)
Dourron, H. M., Strauss, C., Hendricks, P. S. · Pharmacological Reviews (2022)
Radakovic, C., Radakovic, R., Peryer, G. et al. · Journal of Psychedelic Studies (2022)
Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)
Ruffell, S. G. D., Gandy, S., Tsang, W. et al. · Psyarxiv (2022)
Whitney, S., Yaden, D. B., Lipson, J. et al. · Frontiers in Psychology (2022)
McCulloch, D. E-W., Knudsen, G. M., Barrett, F. S. et al. · Neuroscience and Biobehavioral Reviews (2022)
Orłowski, P., Ruban, A., Szczypiński, J. et al. · Journal of Psychopharmacology (2022)
Aharon-Almagor, A., Barrett, F. S. · Research Square (2022)
Maia, L. O., Massarentti, C. M., Tófoli, L.F. · Psychopharmacology (2022)
Barrett, F. S., Zhou, Y., Carbonaro, T. M. et al. · Frontiers in Neuroergonomics (2022)
Dursun, S. M., Kelly, J. R., Gillan, C. M. et al. · Frontiers in Psychiatry (2021)
Rieser, N. M., Herdener, M. ;., Preller, K. H. · Current Topics in Behavioral Neurosciences (2021)
Garcia-Romeu, A., Darcy, S., Jackson, H. et al. · Current Topics in Behavioral Neurosciences (2021)
Kiraga, M. K., Mason, N. L., Uthaug, M. V. et al. · Frontiers in Pharmacology (2021)
Johnson, M. W., Gründer, G., Betzler, F. et al. · Current Addiction Reports (2021)
Domínguez-Clavé, E., Soler, J., Elices, M. et al. · Human Psychopharmacology (2021)
Kočárová, C., Horacek, J., Carhart-Harris, R. L. · Frontiers in Psychiatry (2021)
Wießner, I., Falchi, M., Palhano-Fontes, F. et al. · Psychological Medicine (2021)
Mans, K., Kettner, H., Erritzoe, D. et al. · Frontiers in Psychiatry (2021)
Bement, W., Banks, M. I., Zahid, Z. et al. · Molecular Biology of the Cell (2021)
Mason, N. L., Kuypers, K. P. C., Reckweg, J. T. et al. · Translational Psychiatry (2021)
Payne, J. E., Chambers, R., Liknaitzky, P. · ACS Pharmacology and Translational Science (2021)
Palhano-Fontes, F., Gorman, I., Nielson, E. M. et al. · Frontiers in Psychology (2021)
McCulloch, D. E-W., Madsen, M. K., Stenbæk, D. S. et al. · Journal of Psychopharmacology (2021)
Gandy, S., Forstmann, M., Carhart-Harris, R. L. et al. · Health Psychology Open (2020)
DiVito, A. J., Leger, R. F. · Molecular Biology Reports (2020)
Zeifman, R. J., Wagner, A. C., Watts, R. et al. · Frontiers in Psychiatry (2020)
Pasquini, L., Palhano-Fontes, F., Araújo, D. B. · Journal of Psychopharmacology (2020)
Madsen, M. K., Fisher, P. M., Stenbæk, D. S. et al. · European Neuropsychopharmacology (2020)
Heuschkel, K., Kuypers, K. P. C. · Frontiers in Psychiatry (2020)
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)
Krediet, E., Bostoen, T., Breeksema, J. J. et al. · International Journal of Neuropsychopharmacology (2020)
Jiménez-Garrido, D. F., Gómez-Sousa, M., Ona, G. et al. · Scientific Reports (2020)
Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)
Mertens, L. J., Wall, M. B., Roseman, L. et al. · Journal of Psychopharmacology (2020)
Dos Santos, R. G., Hallak, J. E. · Neuroscience and Biobehavioral Reviews (2020)
Araújo, D. B., Zeifman, R. J., Palhano-Fontes, F. et al. · Frontiers in Pharmacology (2019)
Felix, M., Stefan, B. · Swiss Medical Weekly (2019)
Smigielski, L., Scheidegger, M., Kometer, M. et al. · NeuroImage (2019)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Preller, K. H., Razi, A., Zeidman, P. et al. · PNAS (2019)
Richards, W. A., Garcia-Romeu, A. · International Review of Psychiatry (2018)
Domínguez-Clavé, E., Soler, J., Pascual, J. C. et al. · Psychopharmacology (2018)
Jungaberle, H., Thal, S., Zeuch, A. et al. · Neuropharmacology (2018)
Elices, M., Soler, J., Domínguez-Clavé, E. et al. · Frontiers in Pharmacology (2018)
Carhart-Harris, R. L. · Neuropharmacology (2018)
Barsuglia, J. P., Polanco, M., Palmer, R. et al. · Progress in Brain Research (2018)
Carhart-Harris, R. L., Roseman, L., Bolstridge, M. et al. · Scientific Reports (2017)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.